Circio Enters Research Collaboration With Solid Biosciences To Evaluate Combining CircVec Generation 5 Construct With POLARIS-101 AAV Capsid For Genetic Heart Disease Gene Therapy
Benzinga Newsdesk 10 hours ago
News
The collaboration will evaluate combining the circVec generation 5 construct into POLARIS-101TM to address major unmet medical needs in genetic heart diseaseSolid Biosciences´ proprietary, next-generation AAV capsid,
- The collaboration will evaluate combining the circVec generation 5 construct into POLARIS-101TM to address major unmet medical needs in genetic heart disease
- Solid Biosciences´ proprietary, next-generation AAV capsid, POLARIS-101, was engineered for enhanced cardiac and muscle tropism
- Circio´s latest circVec generation 5 has demonstrated up to 200-fold enhanced gene expression from AAV vectors in heart in vivo